½ÃÀ庸°í¼­
»óǰÄÚµå
1561570

¾ç¸· ½ÃÀå º¸°í¼­ : Á¦Ç°º°, ¿ëµµº°, ÃÖÁ¾ »ç¿ëÀÚº°, Áö¿ªº°(2024-2032³â)

Amniotic Membrane Market Report by Product, Application, End User, and Region 2024-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: IMARC | ÆäÀÌÁö Á¤º¸: ¿µ¹® 143 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ¾ç¸· ½ÃÀå ±Ô¸ð´Â 2023³â 15¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. IMARC GroupÀº ÇâÈÄ ½ÃÀåÀÌ 2024³âºÎÅÍ 2032³â±îÁö 8%ÀÇ ¼ºÀå·ü(CAGR)À» º¸ÀÏ Àü¸ÁÀ̸ç, ½ÃÀåÀº 2032³â±îÁö 32¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù. Àúħ½À(MI) Ä¡·á¿¡ ´ëÇÑ ¼±È£µµ Áõ°¡, ´ç´¢º´ ¹× ·ù¸¶Æ¼½º °üÀý¿°°ú °°Àº ¸¸¼º ÁúȯÀÇ À¯º´·ü Áõ°¡, Àü¹® Ŭ¸®´Ð ¹× º´¿ø È®´ë´Â ½ÃÀåÀ» ÃßÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀÇ ÀϺÎÀÔ´Ï´Ù.

¾ç¸·Àº ŹÝÀÇ ÃÖ³»ÃþÀÌ¸ç µÎ²¨¿î ±âÀú¸·°ú ¹«Ç÷°ü °£Áú ¸ÅÆ®¸¯½º·Î ±¸¼ºµË´Ï´Ù. ¾ç¸·Àº Źݿ¡¼­ À¯·¡ÇÏ´Â »ýü Á¶Á÷À¸·Î, ±× µ¶Æ¯ÇÑ Æ¯¼ºÀ¸·ÎºÎÅÍ ÀÇ·á ¿ëµµ¿¡ ÀÌ¿ëµÇ°í ÀÖ½À´Ï´Ù. ¿°Áõ ¹ÝÀÀÀ» Á¶ÀýÇÏ¿© ¿°ÁõÀ» ¾ïÁ¦Çϰí Á¶Á÷ÀÇ ¼¶À¯È­¿Í ÈäÅ͸¦ ÃÖ¼ÒÈ­ÇÕ´Ï´Ù. °íÅ뽺·¯¿î »óó¿Í È­»ó¿¡ ÁøÁ¤ È¿°ú¸¦ ÁÖ°í Ä¡À¯ ½Ã°£À» ´ÜÃàÇÕ´Ï´Ù. ¾ÈÀüÇÏ°í ³»¾à¼ºÀÌ ³ô°í °ÅºÎ¹ÝÀÀµµ Àû±â ¶§¹®¿¡ °¢¸·±Ë¾ç µî ¾È¸éÀå¾Ö ¼ö¼ú¿¡ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ À¯ÂøÀ» ÁÙÀ̰í ȸº¹À» ÃËÁøÇϱâ À§ÇÑ »ý¹°ÇÐÀû µå·¹½ÌÀç·Îµµ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù.

Àúħ½À(MI) Ä¡·á¿¡ ´ëÇÑ ¼±È£µµ Áõ°¡´Â ´Ù¾çÇÑ ¼ö¼ú¿¡¼­ ¾ç¸·ÀÇ »ç¿ëÀ» Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÇ·á ÀÎÇÁ¶óÀÇ ¼ºÀå°ú Àü¹® Ŭ¸®´Ð°ú º´¿øÀÇ È®ÀåÀº ¾ç¸· Ä¡·á¸¦ ½Ç½ÃÇÏ´Â µ¥ ¸¹Àº ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. ÀÌ ¿Ü¿¡µµ ´Ù¾çÇÑ ¼±µµÀûÀÎ ½ÃÀå ±â¾÷Àº µµ´Þ ¹üÀ§¸¦ È®´ëÇϰí Àü¹® Áö½ÄÀ» °øÀ¯ÇÏ¸ç »õ·Î¿î ½ÃÀå¿¡ ¾×¼¼½ºÇϱâ À§ÇØ M&A(ÇÕº´ ¹× Àμö)¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ±â¾÷Àº Àû±ØÀûÀ¸·Î Á¦Ç° ¶óÀÎÀ» ´Ù¾çÈ­ÇÏ°í ´Ù¾çÇÑ ¼ö¼ú ¹× Ä¡·á ¿ä±¸¿¡ ¸Â´Â ¾ç¸·À» Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ ÀϺΠ±¹°¡ÀÇ Á¤ºÎ´Â ¾ç¸·ÀÇ ÀåÁ¡°ú ¿ëµµ¿¡ ´ëÇÑ ÀÇ·á Àü¹®°¡¿Í ȯÀÚ¸¦ ±³À°Çϱâ À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸¸ç, ÀÌ´Â ÁÁÀº ½ÃÀå Àü¸ÁÀ» Á¦°øÇÕ´Ï´Ù.

¾ç¸· ½ÃÀå µ¿Çâ ¹×ÃËÁø¿äÀÎ :

Àç»ý ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡

´ç´¢º´ ¹× ·ù¸¶Æ¼½º °üÀý¿°°ú °°Àº ¸¸¼º ÁúȯÀÇ À¯º´·üÀÌ Áõ°¡ÇÏ°í ¸¸¼º »óó¿Í ±Ë¾çÀ¸·Î À̾îÁö¹Ç·Î È¿°úÀûÀÎ Ä¡·á¹ýÀÇ Çʿ伺ÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¾ç¸·Àº Çõ½ÅÀûÀÎ ¼Ö·ç¼ÇÀ» Á¦°øÇϰí Ä¡À¯ °úÁ¤À» ÀÚ±ØÇÕ´Ï´Ù. À̿ʹ º°µµ·Î, ´Ù¾çÇÑ °Ç°­»óÅ¿¡ °É¸®±â ½¬¿î ¼¼°è ³ëÀÎ Àα¸ Áõ°¡´Â º¸´Ù ºü¸¥ Ä¡À¯¿Í Á¶Á÷ Àç»ýÀ» ÃËÁøÇÏ´Â Ä¡·áÀÇ Çʿ伺À» Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á¤Çü¿Ü°ú ¹× Ä¡°úÀÇÇаú °°Àº ´Ù¾çÇÑ ÀÇ·á Àü¹® ºÐ¾ß¿¡¼­ ¾ç¸· ä¿ëÀÌ Áõ°¡Çϰí ÀÖ´Â °Íµµ ½ÃÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¼¼Æ÷ÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ°í ¿°ÁõÀ» ¾ïÁ¦ÇÏ´Â ¾ç¸·ÀÇ ´É·ÂÀº ´Ù¸¥ Àç»ý Ä¡·á¿¡¼­ ¾ç¸·ÀÇ Ã¤¿ëÀ» ÃËÁøÇÕ´Ï´Ù.

ÀÇ·á ÀýÂ÷¿¡¼­ ±â¼úÀÇ Áøº¸

÷´Ü±â¼úÀÇ ÅëÇÕÀ¸·Î È¿À²°ú È¿´ÉÀÌ Çâ»óµÈ ¾ç¸·ÀÌ °³¹ßµÇ°í ÀÖ½À´Ï´Ù. ÃÖ÷´Ü ±â¼úÀº ÇʼöÀûÀÎ ¼ºÀå ÀÎÀÚ¿Í Ä¡À¯ Ư¼ºÀ» È®½ÇÇÏ°Ô À¯ÁöÇÏ¸ç ´Ù¾çÇÑ ÀÇ·á ºÐ¾ß¿¡¼­ÀÇ Àû¿ë °¡´É¼ºÀ» ³ô¿©ÁÝ´Ï´Ù. ¾ç¸·Àº Áٱ⼼Æ÷ Ä¡·á ¹× 3Â÷¿ø(3D) ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ°ú °°Àº ÃÖ÷´Ü Ä¡·á¿ÍÀÇ È£È¯¼ºÀ» Á¦°øÇÏ¿© À¯¸®ÇÑ ½ÃÀå Àü¸ÁÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ÅëÇÕÀº º¸´Ù °³º°È­µÇ°í È¿°úÀûÀÎ Ä¡·á¸¦ °¡´ÉÇÏ°Ô Çϰí ȯÀÚ °ü¸®ÀÇ ÁúÀ» Çâ»ó½Ãŵ´Ï´Ù. À̿ʹ º°µµ·Î º¸Á¸¹æ¹ýÀÇ °³¼±À¸·Î º¸´Ù ±ä º¸Á¸±â°£°ú Æø³ÐÀº À¯ÅëÀÌ °¡´ÉÇÏ°Ô µÇ¾î ´Ù¾çÇÑ Áö¿ª ¹× ÇコÄÉ¾î ½Ã½ºÅÛ¿¡¼­ÀÇ Ã¤¿ëÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

Áö¿ø ±ÔÁ¦ ȯ°æ

°¢±¹ÀÇ ±ÔÁ¦±â°üÀº ¾ç¸·ÀÇ Ä¡·áÀû °¡Ä¡¸¦ ÀνÄÇÏ°í ¾ç¸·ÀÇ ÃßÃâ, °¡°ø, º¸Á¸, Àû¿ë¿¡ ´ëÇÑ ¸íÈ®ÇÏ°í ¸íÈ®ÇÑ ÁöħÀ» ½Ç½ÃÇß½À´Ï´Ù. ÀÌ ÁöħÀº ½Ç¹«ÀÇ ±ÕÀϼºÀ» º¸ÀåÇϰí Á¦Ç°ÀÇ Ç°ÁúÀ» À¯ÁöÇÕ´Ï´Ù. À̿ʹ º°µµ·Î, ±ÔÁ¦ ´ç±¹Àº ¸ðµç °ü·Ã ±ÔÄ¢°ú ±âÁØÀÇ Áؼö¸¦ º¸ÀåÇϱâ À§ÇØ ½ÃÀåÀ» Àû±ØÀûÀ¸·Î ¸ð´ÏÅ͸µÇϰí ÀÖ½À´Ï´Ù. Á¤±âÀûÀÎ °Ë»ç, °¨»ç ¹× º¸°í ¿ä±¸ »çÇ×Àº ¾÷°èÀÇ ½Å·Ú¿Í Á¤Á÷À» À¯ÁöÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¶ÇÇÑ ÀÌ ºÐ¾ßÀÇ ¿¬±¸°³¹ßÀ» Àå·ÁÇÏ´Â Á¶¼º±Ý, Àå·Á±Ý, °ü¹Î ÆÄÆ®³Ê½ÊÀ» Æ÷ÇÔÇÑ Áö¿ø Á¤Ã¥À» Á¦°øÇÕ´Ï´Ù. ¿¬±¸ ±â°ü°úÀÇ Çù·ÂÀûÀÎ ³ë·ÂÀº Çõ½ÅÀ» ÃßÁøÇϰí Âü½ÅÇÑ Á¦Ç° ¹× Ä¡·á¹ýÀ» ½ÃÀå¿¡ ³»º¸³¾ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§ ¹× Á¶»ç ¹æ¹ý

  • Á¶»çÀÇ ¸ñÀû
  • ÀÌÇØ°ü°èÀÚ
  • µ¥ÀÌÅÍ ¼Ò½º
    • 1Â÷ Á¤º¸
    • 2Â÷ Á¤º¸
  • ½ÃÀå ÃßÁ¤
    • »óÇâ½Ä Á¢±Ù
    • ÇÏÇâ½Ä Á¢±Ù
  • Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼­¹®

  • °³¿ä
  • ÁÖ¿ä ¾÷°è µ¿Çâ

Á¦5Àå ¼¼°èÀÇ ¾ç¸· ½ÃÀå

  • ½ÃÀå °³¿ä
  • ½ÃÀå ½ÇÀû
  • COVID-19ÀÇ ¿µÇâ
  • ½ÃÀå ¿¹Ãø

Á¦6Àå ½ÃÀå ³»¿ª : Á¦Ç°º°

  • µ¿°áº¸Á¸ ¾ç¸·
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • µ¿°á°ÇÁ¶ ¾ç¸·
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦7Àå ½ÃÀå ³»¿ª : ¿ëµµº°

  • ¼ö¼úâ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ¾È°ú
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ±âŸ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦8Àå ½ÃÀå ³»¿ª : ÃÖÁ¾ »ç¿ëÀÚº°

  • º´¿ø
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • Àü¹® Ŭ¸®´Ð
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ¿¬±¸¼¾ÅÍ ¹× ¿¬±¸¼Ò
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦9Àå ½ÃÀå ³»¿ª : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • Çѱ¹
    • È£ÁÖ
    • Àεµ³×½Ã¾Æ
    • ±âŸ
  • À¯·´
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ·¯½Ã¾Æ
    • ±âŸ
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ³»¿ª : ±¹°¡º°
    • ½ÃÀå ¿¹Ãø

Á¦10Àå SWOT ºÐ¼®

  • °³¿ä
  • °­Á¡
  • ¾àÁ¡
  • ±âȸ
  • À§Çù

Á¦11Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦12Àå Porter's Five Forces ºÐ¼®

  • °³¿ä
  • ±¸¸ÅÀÚÀÇ Çù»ó·Â
  • °ø±Þ±â¾÷ÀÇ Çù»ó·Â
  • °æÀïµµ
  • ½Å±Ô ÁøÀÔ¾÷ÀÚÀÇ À§Çù
  • ´ëüǰÀÇ À§Çù

Á¦13Àå °¡°Ý ºÐ¼®

Á¦14Àå °æÀï ±¸µµ

  • ½ÃÀå ±¸Á¶
  • ÁÖ¿ä ±â¾÷
  • ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏ
    • Amnio Technology LLC
    • Amniox Medical Inc.(TissueTech Inc.)
    • Genesis Biologics
    • Human Regenerative Technologies LLC
    • Integra LifeSciences Holdings Corporation
    • Katena Products Inc.
    • MiMedx Group
    • Next Biosciences
    • Skye Biologics Holdings LLC
    • Smith & Nephew plc
    • Surgenex LLC
    • Ventris Medical LLC
    • Wright Medical Group NV(Stryker BV)
AJY 24.10.08

The global amniotic membrane market size reached US$ 1.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 3.2 Billion by 2032, exhibiting a growth rate (CAGR) of 8% during 2024-2032. The increasing preference for minimally invasive (MI) treatments, rising prevalence of several chronic conditions like diabetes and rheumatoid arthritis, and the expansion of specialized clinics and hospitals are some of the major factors propelling the market.

The amniotic membrane is the innermost layer of the placenta, which consists of a thick basement membrane and an avascular stromal matrix. It is a biological tissue derived from the placenta and utilized in medical applications due to its unique properties. It reduces inflammation by modulating inflammatory responses and minimizes fibrosis and scarring in tissues. It provides a soothing effect on painful wounds and burns and reduces their healing times. It is safe and well-tolerated, with low rejection rates and widely used in surgeries for ocular surface disorders, such as corneal ulcers. It is also employed as a biological dressing to reduce adhesions and enhance recovery.

The increasing preference for minimally invasive (MI) treatments is resulting in the increasing utilization of the amniotic membrane in various surgical procedures. Additionally, growth in healthcare infrastructure and the expansion of specialized clinics and hospitals are offering more opportunities for the implementation of amniotic membrane therapies. Apart from this, various leading market players are focusing on mergers and acquisitions (M&A) to expand their reach, share expertise, and access new markets. Furthermore, companies are actively diversifying their product lines, offering amniotic membranes tailored for various surgical and therapeutic needs. Moreover, governments of several countries are increasing their efforts to educate healthcare professionals and patients about the benefits and applications of amniotic membranes, which is offering a favorable market outlook.

Amniotic Membrane Market Trends/Drivers:

Increasing demand for regenerative medicine

The rising prevalence of several chronic conditions like diabetes and rheumatoid arthritis, leading to chronic wounds and ulcers is increasing the need for effective treatment methods. Amniotic membranes offer an innovative solution and stimulate the healing process. Apart from this, the growing global geriatric population, which is highly susceptible to various health conditions is driving the need for treatments that promote faster healing and tissue regeneration. Furthermore, the increasing adoption of amniotic membranes in various medical specialties like orthopedics and dental medicine is positively influencing the market. Moreover, the ability of the amniotic membrane to facilitate cellular growth and decrease inflammation is driving its adoption in other regenerative treatments.

Technological advancements in medical procedures

The integration of advanced technologies is resulting in the development of amniotic membranes with increased efficiency and efficacy. Modern techniques ensure that essential growth factors and healing properties are maintained, enhancing their applicability in various medical domains. The compatibility of the amniotic membrane with cutting-edge treatments, such as stem cell therapies and three-dimensional (3D) bioprinting, is offering a favorable market outlook. These integrations allow for more personalized and effective treatments and enhance the quality of patient care. Apart from this, improved preservation methods allow for longer shelf life and wider distribution, which is increasing its adoption across various regions and healthcare systems.

Supportive regulatory environment

Regulatory bodies of various countries are recognizing the therapeutic value of the amniotic membrane and implementing clear and well-defined guidelines for the extraction, processing, preservation, and application of amniotic membranes. These guidelines ensure uniformity in practices and uphold the quality of products. Apart from this, regulatory authorities are actively monitoring the market to ensure compliance with all relevant rules and standards. Regular inspections, audits, and reporting requirements help maintain trust and integrity in the industry. Furthermore, they are offering supportive policies, which include grants, incentives, and public-private partnerships that encourage research and development in the field. Collaborative efforts with research institutions can drive innovation and bring novel products and therapies to market.

Amniotic Membrane Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global amniotic membrane market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on product, application and end user.

Breakup by Product:

  • Cryopreserved Amniotic Membrane
  • Lyophilization Amniotic Membrane

Cryopreserved amniotic membrane dominates the market

The report has provided a detailed breakup and analysis of the market based on the product. This includes cryopreserved amniotic membrane and lyophilization amniotic membrane. According to the report, cryopreserved amniotic membrane represented the largest segment.

It has a long shelf life and it allows hospitals and clinics to maintain an inventory without the risk of degradation. It also offers ease of storage, simplifies logistics, and reduces waste. Additionally, it aids in maintaining the biological integrity of the amniotic membrane and enhancing the therapeutic effectiveness of the membrane. This ability to retain the natural healing properties is attracting healthcare providers. Apart from this, regulatory bodies are recognizing the benefits of cryopreservation and are actively providing supportive guidelines and approvals. This support from regulatory authorities is promoting the adoption of cryopreserved amniotic membranes across different regions.

Breakup by Application:

  • Surgical Wounds
  • Ophthalmology
  • Others

Surgical wounds account for the majority of the market share

A detailed breakup and analysis of the market based on the application has also been provided in the report. This includes surgical wounds, ophthalmology, and others. According to the report, surgical wounds hold the majority of the market share. Increasing road accidents and major sports injuries are leading to a rise in elective and emergency surgeries across various medical disciplines, which is catalyzing the need for effective wound care. Additionally, technological advancements in surgical procedures are allowing for more complex and numerous surgeries to be performed with optimal efficiency. Apart from this, the rising focus on minimizing post-operative infections and complications is driving the demand for high-quality wound care products. The growing awareness about the importance of infection prevention and control is encouraging healthcare providers and patients to opt for optimal wound care solutions. Furthermore, rising preferences for effective healing without significant scarring is leading to innovations in wound care products specifically designed for surgical wounds.

Breakup by End User:

  • Hospitals
  • Ambulatory Surgical Centers
  • Specialized Clinics
  • Research Centers and Laboratory

Hospitals hold the largest share of the market

A detailed breakup and analysis of the market based on the end user has also been provided in the report. This includes hospitals, ambulatory surgical centers, specialized clinics, and research centers and laboratory. According to the report, hospitals accounted for the largest market share. They have specialized medical professionals and skilled staff trained to deal with various medical conditions. They can offer enhanced diagnostic and therapeutic procedures as they are equipped with technologically advanced medical equipment. Apart from this, they provide emergency medical services and handle urgent and life-threatening situations, which is offering a favorable market outlook. Furthermore, many hospitals have established relationships with insurance providers, facilitating easier and more comprehensive coverage for patients, which makes hospital-based care more accessible for many individuals. Moreover, hospitals in various regions receive government funding and support, which ensures the availability of essential healthcare services to the wider population.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America exhibits a clear dominance, accounting for the largest amniotic membrane market share

The report has also provided a comprehensive analysis of all the major regional markets, which includes North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and Others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and Others); Latin America (Brazil, Mexico, and Others); and the Middle East and Africa. According to the report, North America accounted for the largest market share since the region is home to leading research institutions and biotechnology companies that actively invest in the research and development (R&D) activities of regenerative medicine, including amniotic membranes. Additionally, the region has a highly developed healthcare system with state-of-the-art facilities and technology, which drives innovation and facilitates the adoption of advanced medical products, such as amniotic membranes. Apart from this, supportive regulatory guidelines for the development, approval, and use of amniotic membrane products in North America is encouraging manufacturers to expand their market reach. Furthermore, collaborations between hospitals, research institutions, and biotechnology companies is enhancing innovation and market penetration in the region.

Competitive Landscape:

Companies are currently engaging in a variety of activities to expand the scope and efficiency of this unique biological material. They are extracting the amniotic membrane from the placenta and are processing it under carefully controlled conditions. Additionally, they are conducting rigorous R&D, exploring new possibilities for amniotic membrane use in regenerative medicine. Apart from this, they are working continuously to enhance the potential of the amniotic membrane, improving the prospects of new therapies, and continuing to support the broader goals of healthcare and patient well-being. Furthermore, many companies are actively involved in educating healthcare providers about the benefits and applications of the amniotic membrane.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • Amnio Technology LLC
  • Amniox Medical Inc. (TissueTech Inc.)
  • Genesis Biologics
  • Human Regenerative Technologies LLC
  • Integra LifeSciences Holdings Corporation
  • Katena Products Inc.
  • MiMedx Group
  • Next Biosciences
  • Skye Biologics Holdings LLC
  • Smith & Nephew plc
  • Surgenex LLC
  • Ventris Medical LLC
  • Wright Medical Group N.V. (Stryker B.V.).

Recent Developments:

  • In February 2022, Amnio Technology LLC launched two new PalinGen membrane products, PalinGen Dual-Layer Membrane and Dual Layer PalinGen X-Membrane. They are minimally manipulated, homologous use and chorion-free.
  • In June 2021, MiMedx Group received reimbursement approval in Japan, making it the first and only amniotic tissue product approved for use in the country.

Key Questions Answered in This Report

  • 1. What was the size of the global amniotic membrane market in 2023?
  • 2. What is the expected growth rate of the global amniotic membrane market during 2024-2032?
  • 3. What are the key factors driving the global amniotic membrane market?
  • 4. What has been the impact of COVID-19 on the global amniotic membrane market?
  • 5. What is the breakup of the global amniotic membrane market based on the product?
  • 6. What is the breakup of the global amniotic membrane market based on the application?
  • 7. What is the breakup of the global amniotic membrane market based on the end user?
  • 8. What are the key regions in the global amniotic membrane market?
  • 9. Who are the key players/companies in the global amniotic membrane market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Amniotic Membrane Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Cryopreserved Amniotic Membrane
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Lyophilization Amniotic Membrane
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Surgical Wounds
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Ophthalmology
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Others
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Ambulatory Surgical Centers
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Specialized Clinics
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Research Centers and Laboratory
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Amnio Technology LLC
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
    • 14.3.2 Amniox Medical Inc. (TissueTech Inc.)
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 Genesis Biologics
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 Human Regenerative Technologies LLC
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Integra LifeSciences Holdings Corporation
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Katena Products Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
    • 14.3.7 MiMedx Group
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
    • 14.3.8 Next Biosciences
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
    • 14.3.9 Skye Biologics Holdings LLC
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
    • 14.3.10 Smith & Nephew plc
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Surgenex LLC
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
    • 14.3.12 Ventris Medical LLC
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
    • 14.3.13 Wright Medical Group N.V. (Stryker B.V.)
      • 14.3.13.1 Company Overview
      • 14.3.13.2 Product Portfolio
      • 14.3.13.3 SWOT Analysis
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦